Reported Sunday, Adagio Medical's FULCRUM-VT Pivotal IDE Trial Meets Safety And Effectiveness Endpoints With 84% Freedom From Shock And 59% Freedom From VT Recurrence

Benzinga Newsdesk www.benzinga.com Positive 95.1%

Neg 0% Neu 0% Pos 95.1%

Comments

No comments yet. Be the first!